Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Astrazeneca Plc ADR (NQ: AZN )

78.02 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,919
Open 78.02
Bid (Size) 77.68 (9)
Ask (Size) 77.74 (7)
Prev. Close 78.02
Today's Range 78.02 - 78.02
52wk Range 60.47 - 79.36
Shares Outstanding N/A
Dividend Yield 1.19%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
From AstraZeneca
Via Business Wire
Stocks Seeing Relentless Buying Pressure; Bonds Are Not
Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year... 
Via Talk Markets

Performance

YTD
+14.06%
+14.06%
1 Month
+9.58%
+9.58%
3 Month
+18.52%
+18.52%
6 Month
+20.96%
+20.96%
1 Year
+8.68%
+8.68%

More News

Read More
IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
From AstraZeneca
Via Business Wire
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
From AstraZeneca
Via Business Wire
Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years
Via Benzinga
3 No-Brainer Stocks to Buy in June
Via The Motley Fool
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
Via The Motley Fool
Topics Stocks
Exposures US Equities
Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug
Via Benzinga
Exposures Product Safety
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
Via The Motley Fool
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
Via The Motley Fool
Cellectis Reports Financial Results for First Quarter 2024
From Cellectis Inc.
Via GlobeNewswire
Why Is AstraZeneca Stock Trading Lower On Tuesday?
Via Benzinga
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Via Benzinga
Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
From AstraZeneca
Via Business Wire
Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings
Via Talk Markets
Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
From AstraZeneca
Via Business Wire
Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity
Via Benzinga
The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5%
Via Talk Markets
AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
From AstraZeneca
Via Business Wire
AstraZeneca Targets Ambitious $80B In Total Revenue By 2030 Through Pipeline Expansion
Via Benzinga
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
From AstraZeneca
Via Business Wire
Large Cap Biopharmaceuticals Performance
Via Talk Markets
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient Population
Via Benzinga
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.